Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.

Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA.

Clin Cancer Res. 2018 Jul 15;24(14):3348-3357. doi: 10.1158/1078-0432.CCR-17-3059. Epub 2018 Apr 4.

PMID:
29618616
2.

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.

3.

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.

Lenz HJ, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L, Bondarde S, Dobbs T, Tagliaferri M, Hoch U, Hannah AL, Berkowitz M.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1161-1169. doi: 10.1007/s00280-017-3438-y. Epub 2017 Oct 17.

PMID:
29043412
4.

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch U, Tagliaferri M, Hannah AL, Garcia AA.

Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19.

PMID:
28935273
5.

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Nov;166(1):327-328. doi: 10.1007/s10549-017-4482-3. No abstract available.

PMID:
28884461
6.

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.

Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J.

PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017.

7.

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J.

Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13. Erratum in: Breast Cancer Res Treat. 2017 Nov;166(1):327-328.

8.

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.

9.

Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.

Sy SK, Sweeney TD, Ji C, Hoch U, Eldon MA.

Cancer Chemother Pharmacol. 2017 Jan;79(1):57-67. doi: 10.1007/s00280-016-3192-6. Epub 2016 Nov 30.

10.

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.

Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J.

Springerplus. 2016 Jul 8;5(1):1033. doi: 10.1186/s40064-016-2446-4. eCollection 2016.

11.

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, Ali CF, Chang TK, Konakova M, Pena RL, Kanhere RS, Kirksey YM, Ji C, Wang Y, Huang J, Sweeney TD, Kantak SS, Doberstein SK.

Clin Cancer Res. 2016 Feb 1;22(3):680-90. doi: 10.1158/1078-0432.CCR-15-1631.

12.

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J.

Lancet Oncol. 2015 Nov;16(15):1556-1568. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22.

PMID:
26482278
13.

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.

Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall T, Mohan NK, Eldon MA, Hoch U, Lockman PR.

BMC Cancer. 2015 Oct 13;15:685. doi: 10.1186/s12885-015-1672-4.

14.

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

Hoch U, Staschen CM, Johnson RK, Eldon MA.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37. doi: 10.1007/s00280-014-2577-7. Epub 2014 Sep 17.

15.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group.

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.

PMID:
24095299
16.

A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.

Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A, Hinshaw I, Jotte R, Rosen LS, Hoch U, Eldon MA, Medve R, Schroeder K, White E, Von Hoff DD.

Clin Cancer Res. 2013 Jan 1;19(1):268-78. doi: 10.1158/1078-0432.CCR-12-1201. Epub 2012 Nov 7.

17.

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J, Arkin MR, Evanchik MJ, Flanagan WM, Hoch U, Hyde J, Prabhu S, Silverman JA, Wright J.

ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. doi: 10.1021/ml2002482. eCollection 2012 Mar 8.

18.

Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.

Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC.

J Thorac Oncol. 2011 Feb;6(2):384-6. doi: 10.1097/JTO.0b013e318200e509.

19.

Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

Zhong M, Hanan EJ, Shen W, Bui M, Arkin MR, Barr KJ, Evanchik MJ, Hoch U, Hyde J, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):307-10. doi: 10.1016/j.bmcl.2010.11.014. Epub 2010 Nov 5.

PMID:
21109434
20.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

Zhong M, Shen W, Barr KJ, Arbitrario JP, Arkin MR, Bui M, Chen T, Cunningham BC, Evanchik MJ, Hanan EJ, Hoch U, Huen K, Hyde J, Kumer JL, Lac T, Lawrence CE, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. doi: 10.1016/j.bmcl.2010.06.145. Epub 2010 Jul 23.

PMID:
20655213
21.

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG.

J Clin Oncol. 2010 Jun 20;28(18):3015-22. doi: 10.1200/JCO.2009.26.1347. Epub 2010 May 17.

22.

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC.

Clin Cancer Res. 2010 Apr 1;16(7):2167-75. doi: 10.1158/1078-0432.CCR-09-2236. Epub 2010 Mar 16.

23.

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.

Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, Harris SO, Hashash A, Hoch U, Hogan JN, Howlett AR, Jacobs JW, Lam JW, Ritchie SC, Romanowski MJ, Silverman JA, Stockett DE, Teague JN, Zimmerman KM, Taverna P.

Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. doi: 10.1007/s00280-009-1076-8. Epub 2009 Aug 1.

PMID:
19649632
24.

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowski MJ, Silverman JA, Tangonan BT, Taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O'Brien T, Lew W.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5158-61. doi: 10.1016/j.bmcl.2009.07.016. Epub 2009 Jul 9.

PMID:
19646866
25.

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.

Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA, Hawtin RE.

Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32. doi: 10.1007/s00280-008-0921-5. Epub 2009 Jan 24.

PMID:
19169685
26.

Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.

Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U.

Drug Metab Dispos. 2009 Mar;37(3):594-601. doi: 10.1124/dmd.108.023432. Epub 2008 Dec 12.

PMID:
19074528
27.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
28.

Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio.

Fan J, Fahr B, Stockett D, Chan E, Cheeti S, Serafimova I, Lu Y, Pham P, Walker DH, Hoch U, Choong IC.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6236-9. doi: 10.1016/j.bmcl.2008.09.099. Epub 2008 Oct 2.

PMID:
18926699
29.

A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.

Choong IC, Serafimova I, Fan J, Stockett D, Chan E, Cheeti S, Lu Y, Fahr B, Pham P, Arkin MR, Walker DH, Hoch U.

Bioorg Med Chem Lett. 2008 Nov 1;18(21):5763-5. doi: 10.1016/j.bmcl.2008.09.073. Epub 2008 Sep 24.

PMID:
18842409
30.

Discovery of a potent and selective aurora kinase inhibitor.

Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S, Heumann SA, Hoch U, Jacobs JW, Lam J, Lawrence CE, McDowell RS, Nannini MA, Shen W, Silverman JA, Sopko MM, Tangonan BT, Teague J, Yoburn JC, Yu CH, Zhong M, Zimmerman KM, O'Brien T, Lew W.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. doi: 10.1016/j.bmcl.2008.07.073. Epub 2008 Jul 24.

PMID:
18678489
31.

Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.

Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW.

Antimicrob Agents Chemother. 2004 Dec;48(12):4835-42.

32.

EpoK, a cytochrome P450 involved in biosynthesis of the anticancer agents epothilones A and B. Substrate-mediated rescue of a P450 enzyme.

Ogura H, Nishida CR, Hoch UR, Perera R, Dawson JH, Ortiz de Montellano PR.

Biochemistry. 2004 Nov 23;43(46):14712-21.

PMID:
15544342
33.

Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.

Gross M, Clements J, Beckett RP, Thomas W, Taylor S, Lofland D, Ramanathan-Girish S, Garcia M, Difuntorum S, Hoch U, Chen H, Johnson KW.

J Antimicrob Chemother. 2004 Mar;53(3):487-93. Epub 2004 Feb 12.

PMID:
14963065
34.

Pharmacology of novel heteroaromatic polycycle antibacterials.

Gross M, Bürli R, Jones P, Garcia M, Batiste B, Kaizerman J, Moser H, Jiang V, Hoch U, Duan JX, Tanaka R, Johnson KW.

Antimicrob Agents Chemother. 2003 Nov;47(11):3448-57.

35.

Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family.

LeBrun LA, Hoch U, Ortiz de Montellano PR.

J Biol Chem. 2002 Apr 12;277(15):12755-61. Epub 2002 Jan 30.

37.

Covalently linked heme in cytochrome p4504a fatty acid hydroxylases.

Hoch U, Ortiz De Montellano PR.

J Biol Chem. 2001 Apr 6;276(14):11339-46. Epub 2001 Jan 3.

38.

Molecular basis for the omega-regiospecificity of the CYP4A2 and CYP4A3 fatty acid hydroxylases.

Hoch U, Falck JR, de Montellano PR.

J Biol Chem. 2000 Sep 1;275(35):26952-8.

39.

Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases.

Hoch U, Zhang Z, Kroetz DL, Ortiz de Montellano PR.

Arch Biochem Biophys. 2000 Jan 1;373(1):63-71.

PMID:
10620324
40.

Biotransformations with peroxidases.

Adam W, Lazarus M, Saha-Möller CR, Weichold O, Hoch U, Häring D, Schreier P.

Adv Biochem Eng Biotechnol. 1999;63:73-108. Review.

PMID:
9933982

Supplemental Content

Support Center